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Abstract
This guideline is the second in the line of three for fungal diseases by ESCMID and other societies. The guideline tried to follow the AGREE
criteria for the development of clinical guidelines. This guideline serves as a European and potentially world-wide recommendation for the
diagnosis and management of rare and emerging fungi. They include mucormycosis, hyalohyphomycosis (Fusarium, Paecilomyces,
Scedosporium, etc.), phaeohyphomycosis (Alternaria, Bipolaris, Cladosporium, Rhinocladiella, etc.), and emerging yeasts (Saccharomyces,
Trichosporon, Rhodotorula, etc.).
Introduction
The European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) and European Confederation of Medical
Mycology (ECMM) wanted to tackle a challenge that no major
scientiﬁc society had tried: providing a guideline on the
diagnosis and management of rare and emerging fungal
diseases. This guideline would obviously exclude Candida and
Aspergillus diseases. Practically all invasive fungal diseases (IFD),
including invasive candidiasis and aspergillosis, appear to be
rare and emerging infections by deﬁnition. Although many IFD
are still numerically rare, physicians treating immunosup-
pressed patients are increasingly confronted with a wide
variety of fungal pathogens. Rarity of disease is deﬁned by their
absolute frequency in a population, and deﬁnitions range
around 1 in 2000. Of course these statistics are different for
populations of severely ill patients, where frequencies of IFD
are much higher.
In the context of the numerically increasing patient
population with immunosuppression and the expanding use
of antifungal agents against common pathogens such as Candida
and Aspergillus, the number of patients with IFD due to
emerging and often drug-resistant pathogens is rising [1].
Still, the epidemiology of many of these rare and emerging
infections is not well studied, but joint multinational efforts
supported by the European Fungal Infection Study Group
(EFISG) of the ESCMID, the ECMMand the International Society
for Human and Animal Mycology (ISHAM) are underway [2–5].
Delayed diagnosis of IFD is a well-described problem
associated with increasing mortality [5–9]. For this reason, we
aim to guide physicians on the clinical characteristics, diagnos-
tic utilities and appropriate treatment choice in an area of
many unmet medical needs, where almost no well-designed
randomized clinical trials have been conducted. In addition,
new diagnostic utilities are being implemented and together
with the growth of the antifungal armamentarium, guidelines
for the correct utilization in the clinical setting are urgently
needed. The implementation of a pan-European guideline may
help national societies to strengthen their local guidelines in
patient care of invasive fungal diseases.
Methods
Organizational structure: This guideline follows the structure
and deﬁnitions of the ESCMID Guideline on Candida diseases
[7,10–14]. It is in accordance with the GRADE and AGREE
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
EDITORIAL 10.1111/1469-0691.12569
systems with minor exceptions [15,16]. To adequately address
the diversity of human fungal pathogens and to facilitate using
the guideline we divided the recommendations into four
groups: (i) Mucormycosis, Cornely et al., (ii) Hyalohypho-
mycosis (Fusarium, Paecilomyces, Scedosporium) Lass-Fl€orl et al.,
(iii) Phaeohyphomycosis (Alternaria, Bipolaris, Cladosporium,
Rhinocladiella) Chowdhary et al., and (iv) emerging yeasts
(Saccharomyces, Trichosporon, Rhodotorula), Arendrup et al.
Members of EFISG-ESCMID and/or ECMM representing 12
European countries were invited to develop the guideline as
experts. Emerging fungal diseases differ in their regional
distribution patterns even more than candidiasis and aspergil-
losis, so we strengthened the group expertise by inviting
non-European mycologists as well.
Time schedule: In January 2012 experts were contacted by
the conveners (OAC, JM), and the chairs of the four subgroups
agreed to coordinate efforts. Meetings were held mostly as
telephone conferences with face-to-face meetings during ECC-
MID in London in April 2012, ISHAM in Berlin in June 2012, and
stand-alone conferences in Cologne in October 2012 and
Copenhagen in November 2012, and ﬁnally recommendations
were presented at ECCMID in Berlin in April 2013.
Practical Working Procedure: We followed a seven-step
approach tabulating published literature and expert opinion on
emerging fungal diseases in a transparent fashion.
For each clinical or microbiological setting or question the
adequate population was deﬁned, followed by the intention of
an intervention or diagnostic procedure. Then the procedure
itself was detailed, followed by the strength of recommenda-
tion (Table 1) and the level of evidence (Table 2), and the
literature supporting this recommendation. Additional
explanations or comments were added if they were felt to
be necessary. From this set of tables the slides for ECCMID
presentations were chosen, and the manuscripts were drafted.
During the development of these guidelines we used
AGREE criteria for their development [15]. As these guidelines
face the task of providing guidance explicitly for rare and
emerging fungi, an evidence-based evaluation remains daunting.
Nevertheless, the working steps were clear and developed and
communicated within the group:
1. Scope and Purpose:
All diseases and their corresponding patient groups were
predeﬁned and appropriately covered by the guideline.
2. Stakeholder involvement:
Due to the nature of the guideline meaning that the incidence
rates are low and diversity of patient groups is wide, patients’
views could not be sought. But the end-users were clearly
deﬁned by these guidelines.
These guidelines are made in collaboration between ECMM
and ESCMID.
3. Rigour of development: The steps of development are similar
to those used for the previous guideline of our group [14]:
a. Deﬁning the rare and emerging fungi.
b. Several manuscripts of individual writing groups that were
established with separate chairs and corresponding
mandates composed these guidelines. The entire guideline
project was then reviewed by the whole guideline group.
c. Predeﬁning questions that need to be answered.
d. Providing alternative answers, all weighted by the body of
evidence.
e. Literature research was performed in PubMed with
predeﬁned search algorithms including major scientiﬁc
meetings (e.g. ICAAC and ECCMID).
f. Slide kits were prepared and circulated within the whole
group for commentary.
g. Presentation of the guidelines during ECCMID 2013.
h. Manuscript is prepared including all valid commentary
during the ECCMID and again circulated within the entire
group for approval.
i. An updated guideline will be routinely available after 4–
5 years after the previous publication. An earlier update
will follow if new and striking changes are found in the
body of evidence.
4. Clarity of presentation:
a. All recommendations are speciﬁc and unambiguous. The
major messages are provided in tables designed to be
easily read and understood.
TABLE 1. Deﬁnition of the Strength of Recommendation
Grad ESCMID-EFISG and ECMM
A strongly support a recommendation for use
B moderately support a recommendation for use
C marginally support a recommendation for use
D support a recommendation against use
TABLE 2. Deﬁnition of the Quality of Evidence
ESCMID-EFISG and ECMM
Level
I Evidence from at least one properly designed randomized, controlled trial
II Evidence from at least one well-designed clinical trial, without
randomization; from cohort or case–control analytic studies (preferably
from more than one centre); from multiple time series; or from dramatic
results of uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical
experience, descriptive case studies, or reports of expert committees
Index
r Meta-analysis or systematic review of randomized controlled trials
t Transferred evidence, i.e. results from different patient cohorts, or similar
immune-status situation
h Comparator group is a historical control
u Uncontrolled trial
a Abstract published at an international meeting
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b. Clear statements of the intention of each single recom-
mendation and clarity regarding its intervention.
5. Applicability:
a. One of the early criteria required by AGREE was the
request to consider the potential cost implication by the
application of the given recommendation. This is not really
feasible in a European guideline because reimbursements
differ between countries and some only look at acquisition
cost without considering the other outcome analyses.
Therefore this criterion could not be considered for each
recommendation.
b. The guidelines want to provide clear guidance to each
clinician and microbiologist and recommend adaptation
and individual modiﬁcations according to each hospital or
country’s epidemiology and abilities, without considering
itself to be the whole truth of diagnosis or treatment.
6. Editorial independence:
a. These guidelines are free of any pharmaceutical company
inﬂuence. No single member of pharmaceutical companies
was present during the guideline discussions.
b. A grant was provided for the development of these
guidelines by ESCMID and ECMM.
c. The guideline was peer-reviewed before its publication.
The previous deﬁnition for the strength of recommendation
and quality of evidence in the ESCMID for Candida disease was
again adopted for this guideline [14]. In brief, the four category
grading system for the ‘strength of a recommendation’ was
employed. Two extreme ends of the grading system were
important: (A) ESCMID/ECMM strongly support a recommen-
dation for use and, at the other end, (D) ESCMID/ECMM
recommend against the use. This differentiation was important
to clearly deﬁne treatment management for or against use of
certain interventions. The two other middle graded statements
(B and C) weighted in the evidence available for its recom-
mendation and could be considered optional (Table 1). For this
guideline we did adopt the strength of recommendation for the
diagnostic part of the guideline.
The criteria for the quality of evidence did not differ from
the previous guidelines [7,10–12,14].
Conclusions
This guideline is the second in a row of three grouped
guidelines by ESCMID and others for the diagnosis and
management of fungal diseases. Other groups are now
adopting the ESCMID strength of recommendation and quality
of evidence as well (ESCMID Study Group for Clostridium
difﬁcile [17], and ESCMID Study Group for Bioﬁlms). This
guideline serves as guidance in the clinical care of patients in
Europe and potentially worldwide. Although guidelines are
helpful tools for everyday decision-making, a clinical judgement
call for the individual patient remains the main fundamental
requirement for the physician in charge.
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